## Fei Li

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6111697/publications.pdf

Version: 2024-02-01

516215 476904 1,047 74 16 29 citations h-index g-index papers 1504 83 83 83 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. Clinical Cancer Research, 2015, 21, 2399-2411.	3.2	106
2	Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: a retrospective study of increasing awareness of a disease from a single-center in China. Orphanet Journal of Rare Diseases, 2015, 10, 20.	1.2	80
3	A systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions. Oncotarget, 2017, 8, 59977-59985.	0.8	63
4	Low serum mi <scp>R</scp> â€19a expression as a novel poor prognostic indicator in multiple myeloma. International Journal of Cancer, 2015, 136, 1835-1844.	2.3	60
5	Targeted inhibition of Focal Adhesion Kinase Attenuates Cardiac Fibrosis and Preserves Heart Function in Adverse Cardiac Remodeling. Scientific Reports, 2017, 7, 43146.	1.6	50
6	Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS). Clinical Reviews in Allergy and Immunology, 2016, 50, 55-63.	2.9	48
7	Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget, 2016, 7, 19589-19600.	0.8	45
8	MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma. Oncotarget, 2015, 6, 38270-38282.	0.8	44
9	Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Medical Oncology, 2014, 31, 902.	1.2	36
10	Bioactive furanocoumarins from stems of Clausena lansium. Phytochemistry, 2014, 107, 141-147.	1.4	33
11	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. Journal of Clinical Investigation, 2022, 132, .	3.9	30
12	Ruxolitinibâ€combined doxorubicinâ€etoposideâ€methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a singleâ€arm, multicentre, phase 2 trial. British Journal of Haematology, 2021, 193, 761-768.	1.2	24
13	Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Leukemia Research, 2015, 39, 793-799.	0.4	22
14	Four new sesquiterpenes from the stems of Pogostemon cablin. Fìtoterapìâ, 2013, 86, 183-187.	1.1	20
15	Acute myeloid leukemia with a novel CPSF6â€RARG variant is sensitive to homoharringtonine and cytarabine chemotherapy. American Journal of Hematology, 2020, 95, E48-E51.	2.0	19
16	Epidemiological investigation of hemophagocytic lymphohistiocytosis in China. Orphanet Journal of Rare Diseases, 2021, 16, 342.	1.2	19
17	Basiliximab for steroidâ€refractory acute graftâ€versusâ€host disease: A realâ€world analysis. American Journal of Hematology, 2022, 97, 458-469.	2.0	19
18	Age- and Sex-Related Aortic Valve Dysfunction and Aortopathy Difference in Patients with Bicuspid Aortic Valve. International Heart Journal, 2019, 60, 637-642.	0.5	18

#	Article	IF	CITATIONS
19	Bone marrow mesenchymal stem cell-derived exosomes induce the Th17/Treg imbalance in immune thrombocytopenia through miR-146a-5p/IRAK1 axis. Human Cell, 2021, 34, 1360-1374.	1.2	16
20	Detection of recurrent cytogenetic aberrations in multiple myeloma: A comparison between MLPA and iFISH. Oncotarget, 2015, 6, 34276-34287.	0.8	15
21	De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e782-e790.	0.2	14
22	Two new neolignans from the stems of <i>Euonymus oblongifolius </i> . Journal of Asian Natural Products Research, 2012, 14, 755-758.	0.7	12
23	Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma. Frontiers in Oncology, 2019, 9, 722.	1.3	12
24	Increased levels of serum interleukin-10 are associated with poor outcome in adult hemophagocytic lymphohistiocytosis patients. Orphanet Journal of Rare Diseases, 2021, 16, 347.	1.2	12
25	Bioactive isopimarane diterpenoids from the stems of Euonymus oblongifolius. Phytochemistry, 2017, 135, 144-150.	1.4	11
26	Small-sized extracellular vesicles (EVs) derived from acute myeloid leukemia bone marrow mesenchymal stem cells transfer miR-26a-5p to promote acute myeloid leukemia cell proliferation, migration, and invasion. Human Cell, 2021, 34, 965-976.	1.2	11
27	A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL) Journal of Clinical Oncology, 2021, 39, 7529-7529.	0.8	11
28	Treatment Advances in EBV Related Lymphoproliferative Diseases. Frontiers in Oncology, 2022, 12, 838817.	1.3	11
29	Structural Valve Deterioration after Transcatheter Aortic Valve Implantation Using J-Valve: A Long-Term Follow-Up. Annals of Thoracic and Cardiovascular Surgery, 2020, 26, 158-165.	0.3	10
30	Disparity analysis and prognostic value of pretreatment whole blood ⟨scp⟩Epsteinâ€Barr⟨ scp⟩ virus ⟨scp⟩DNA⟨ scp⟩ load and Epsteinâ€Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group. International Journal of Cancer, 2022, 150, 327-334.	2.3	10
31	Gut Microbiota and Urine Metabonomics Alterations in Constitution after Chinese Medicine and Lifestyle Intervention. The American Journal of Chinese Medicine, 2021, 49, 1165-1193.	1.5	9
32	Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma. Oncotarget, 2015, 6, 9434-9444.	0.8	9
33	The Efficacy and Mechanism of Chinese Herbal Medicines in Lowering Serum Uric Acid Levels: A Systematic Review. Frontiers in Pharmacology, 2020, 11, 578318.	1.6	8
34	Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China. Leukemia and Lymphoma, 2021, 62, 2657-2664.	0.6	8
35	A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy. Therapeutic Advances in Hematology, 2022, 13, 204062072210851.	1.1	8
36	Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma. Cancer Letters, 2015, 366, 173-181.	3.2	7

#	Article	IF	Citations
37	Short- and Long-Term Outcome after Emergent Cardiac Surgery during Transcatheter Aortic Valve Implantation. Annals of Thoracic and Cardiovascular Surgery, 2021, 27, 112-118.	0.3	7
38	Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study. BMC Medicine, 2022, 20, 108.	2.3	7
39	Qi-Deficiency Related Increases in Disease Susceptibility Are Potentially Mediated by the Intestinal Microbiota. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-10.	0.5	6
40	Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia. BMC Cancer, 2019, 19, 935.	1.1	6
41	Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. BMC Cancer, 2015, 15, 555.	1.1	5
42	Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report. Anti-Cancer Drugs, 2022, 33, e769-e775.	0.7	5
43	Optimization of 4D flow MRI velocity field in the aorta with divergence-free smoothing. Medical and Biological Engineering and Computing, 2021, 59, 2237-2252.	1.6	5
44	Comparison of Procedural and 1-Year Clinical Results of Transcatheter Aortic Valve Implantation Using Prostheses with Different Design of Support Frame. International Heart Journal, 2020, 61, 1196-1203.	0.5	5
45	Identification of a new cryptic PML-RARÎ $\pm$ fusion gene without t(15;17) and biallelic CEBPA mutation in a case of acute promyelocytic leukemia: a case detected only by RT-PCR but not cytogenetics and FISH. Cancer Biology and Therapy, 2020, 21, 309-314.	1.5	4
46	Downregulation of miR-142a Contributes to the Enhanced Anti-Apoptotic Ability of Murine Chronic Myelogenous Leukemia Cells. Frontiers in Oncology, 2021, 11, 718731.	1.3	4
47	Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion. Journal of International Medical Research, 2021, 49, 030006052110632.	0.4	4
48	Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI) Journal of Clinical Oncology, 2021, 39, e20002-e20002.	0.8	3
49	A Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia (SAA). Blood, 2020, 136, 3-4.	0.6	3
50	Contributing Factor of Proximal Arch Dilation in Patients with Bicuspid Aortic Valveâ€"Wall Shear Stress or Upward Extension of Ascending Aorta Dilation?. Heart Surgery Forum, 2020, 23, E435-E440.	0.2	3
51	Acute B lymphoblastic leukemia developing in patients with multiple myeloma: Presentation of Two Cases. Turkish Journal of Haematology, 2019, 36, 287-289.	0.2	3
52	MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4. Bioengineered, 2024, $15$ , .	1.4	3
53	Safety and efficacy of a humanized <scp>CD19</scp> chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology, 2022, 97, 711-718.	2.0	3
54	Ginger Extract Decreases Susceptibility to Dextran Sulfate Sodium-Induced Colitis in Mice Following Early Antibiotic Exposure. Frontiers in Medicine, 2021, 8, 755969.	1.2	3

#	Article	IF	CITATIONS
55	A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL) Journal of Clinical Oncology, 2022, 40, 7543-7543.	0.8	3
56	Acute Myeloid Leukemia with Myelodysplasia-Related Changes in a Patient with Crohn's Disease Treated with Immunosuppressive Therapy. Case Reports in Oncology, 2018, 11, 573-576.	0.3	2
57	Haemophagocytic lymphohistiocytosis occurred during induction chemotherapy in an acute monocytic leukemia patient with FLT3-ITD and DNMT3A mutations. BMC Cancer, 2018, 18, 604.	1.1	2
58	The Heterogeneous Phenotype of Bicuspid Aortopathy Attribute to Different Dominant Pathogenesis. Annals of Thoracic and Cardiovascular Surgery, 2019, 25, 265-273.	0.3	2
59	Results from a Phase 2 Study of a Novel Janus Kinase Inhibitor in Treatment of Patients with Myelofibrosis. Blood, 2021, 138, 387-387.	0.6	2
60	Left Ventricular Myocardial Remodeling and Prognostic Marker Derived from Postmyectomy Cardiac MRI Feature Tracking in Hypertrophic Obstructive Cardiomyopathy. Radiology: Cardiothoracic Imaging, 2022, 4, e210172.	0.9	2
61	Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival. Leukemia Research, 2014, 38, 666-672.	0.4	1
62	<scp>BH</scp> 3 mimetic <scp>ABT</scp> â€₹37 induces apoptosis in <scp>CD</scp> 34 <sup>+</sup> acute myeloid leukemia cells and shows synergistic effect with conventional chemotherapeutic drugs. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e144-e152.	0.7	1
63	791â€A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL). , 2020, , .		1
64	MiR-137 Contributes to Drug Susceptibility and Chromosomal Instability of Multiple Myeloma through Targeting AURKA. Blood, 2014, 124, 5715-5715.	0.6	1
65	The Etiological Heterogeneity of Bicuspid Aortopathy between Ascending and Root Morphotype. Heart Surgery Forum, 2020, 23, E913-E919.	0.2	1
66	ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T). Blood, 2021, 138, 4778-4778.	0.6	1
67	Changes of Peripheral Blood Lymphocyte Subsets and Cytokines in Patients with Multiple Myeloma and Their Clinical Significance. Blood, 2020, 136, 38-38.	0.6	1
68	Retrospective Study of the Relationship between Variable Benign Epilepsy of Childhood with Centrotemporal Spikes and the Changes of Zinc, MRS, VEEG, and IQ Test. Disease Markers, 2022, 2022, 1-4.	0.6	1
69	Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study. Blood, 2021, 138, 1359-1359.	0.6	0
70	Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI). Blood, 2021, 138, 4770-4770.	0.6	0
71	A Multicenter Real-Life Study of Polatuzumab Vedotin Combined with Immunochemotherapy in Patients with R/R DLBCL: Preliminary Data on Efficacy and Safety in Chinese Cohort. Blood, 2020, 136, 50-51.	0.6	O
72	Waldenström's Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals. Blood, 2020, 136, 5-6.	0.6	0

#	Article	IF	CITATIONS
73	Evaluation of Bone Marrow Fibrosis and Lymphocyte Subsets in Adult Patients with Primary Immune Thrombocytopenia and Correlation with Clinical Findings. Blood, 2020, 136, 39-39.	0.6	O
74	A phase II, multicenter, single-arm study of parsaclisib, a PI3Kδ inhibitor, in relapsed or refractory follicular lymphoma in China: Updated data from the study Journal of Clinical Oncology, 2022, 40, 7574-7574.	0.8	0